Roche Group

Roche Group. The Roche Group is a global pioneer in pharmaceuticals and diagnostics, operating under a unified approach to advance personalised healthcare. Founded in Basel, Switzerland, it has grown into one of the world's largest biotechnology companies and a leading provider of in vitro diagnostics. Its strategy integrates innovative medicines with diagnostic tests to improve patient outcomes across major disease areas like oncology, immunology, and neurology.

History

The company was established in 1896 by Fritz Hoffmann-La Roche, who envisioned a future for industrial-scale pharmaceutical manufacturing. An early breakthrough came with the production of thyroid extract and the cough suppressant Sirolin. Under the leadership of Fritz's son, Emanuel Hoffmann, the firm expanded internationally, opening subsidiaries in New York City and London. A landmark achievement was the first synthetic production of vitamin C, branded as Redoxon, in 1934, followed by the development of benzodiazepines like Librium and Valium in the mid-20th century. The 1990 acquisition of a majority stake in Genentech in South San Francisco marked a pivotal strategic shift, cementing its leadership in biotechnology. Subsequent major acquisitions included Ventana Medical Systems in 2008 and the full integration of Genentech in 2009, alongside the purchase of Foundation Medicine in 2018 to strengthen its genomics and oncology portfolio.

Business segments

The company's operations are divided into two core sectors. The Pharmaceuticals division focuses on developing and commercialising novel medicines, with a strong emphasis on oncology, immunology, infectious diseases, ophthalmology, and neuroscience. This division markets key products like Ocrevus and Hemlibra. The Diagnostics division is the world's leading provider of in vitro diagnostics, offering a broad portfolio that includes instruments and tests used in clinical laboratories and point-of-care testing. This segment is further organised into areas such as Diabetes Care, Molecular Diagnostics, Tissue Diagnostics, and Centralised and Point of Care Solutions. The division's products, including the cobas systems, are essential for disease screening, monitoring, and guiding treatment decisions.

Research and development

Its research engine is driven by a network of global sites, including the flagship Roche Innovation Center Basel and the Genentech Research and Early Development hub. The approach heavily leverages biomarker discovery and companion diagnostics to enable targeted therapy. Significant investments are made in cutting-edge modalities such as bispecific antibodies, small molecules, and gene therapy. Collaborations with academic institutions like the Broad Institute and partnerships with companies such as Adaptive Biotechnologies are central to its strategy. The pRED (Pharma Research and Early Development) and gRED (Genentech Research and Early Development) organisations pursue independent yet complementary research agendas, focusing on translating scientific discoveries into clinical candidates across diverse therapeutic areas.

Corporate affairs

The company is incorporated in Switzerland and its shares are listed on the SIX Swiss Exchange. The Roche family, through their pooled voting shares, retain a significant influence on corporate matters. Its global headquarters remains in Basel, with major operational sites in Pleasanton, California for diagnostics and South San Francisco for pharmaceuticals. The firm is consistently ranked highly in the Access to Medicine Index and engages in numerous access programs to improve medicine availability in low- and middle-income countries. It is a founding member of the AMR Action Fund to combat antimicrobial resistance and maintains active partnerships with global health bodies like the World Health Organization and the Bill & Melinda Gates Foundation.

Key products

Its portfolio includes several blockbuster medicines and diagnostic systems. In oncology, major therapies include Herceptin for HER2-positive breast cancer, Avastin targeting angiogenesis, and Tecentriq, an immune checkpoint inhibitor. In neuroscience, Ocrevus is a leading treatment for multiple sclerosis, while Evrysdi addresses spinal muscular atrophy. The immunology portfolio features Actemra for rheumatoid arthritis. In diagnostics, the cobas platform series is ubiquitous in laboratories for molecular testing of diseases like HIV and hepatitis C, and the VENTANA systems are the standard in anatomical pathology for cancer diagnosis. The Accu-Chek system is widely used for diabetes management.

Category:Pharmaceutical companies of Switzerland Category:Companies listed on the SIX Swiss Exchange Category:Biotechnology companies